Litcher-Kelly, L. Et Al. 2024. Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments. Orphanet Journal of Rare Diseases , vol.19, no.1 .

Litcher-Kelly, L., ÖZEN, A. O., Ollis, S., Feldman, H. B., Yaworsky, A., Medrano, P., ... Chongsrisawa, V.(2024). Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments. Orphanet Journal of Rare Diseases , vol.19, no.1.

Litcher-Kelly, Leighann Et Al. "Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments," Orphanet Journal of Rare Diseases , vol.19, no.1, 2024

Litcher-Kelly, Leighann Et Al. "Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments." Orphanet Journal of Rare Diseases , vol.19, no.1, 2024

Litcher-Kelly, L. Et Al. (2024) . "Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments." Orphanet Journal of Rare Diseases , vol.19, no.1.

@article{article, author={Leighann Litcher-Kelly Et Al. }, title={Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments}, journal={Orphanet Journal of Rare Diseases}, year=2024}